pharma · Primary Mitochondrial Myopathy · Advanced Solid Tumors, Advanced Breast Cancer · OKUR
OnKure Therapeutics
OnKure Therapeutics patent portfolio — 7 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Boulder, USA
- Founded
- 2011
- Employees
- 42
- Programs
- 8
- Drugs
- 4
- Patents
- 7
OnKure Therapeutics patents
7 pharmaceutical patents indexed for OnKure Therapeutics. 0 expire within 24 months.
OnKure Therapeutics has 7 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12252511
Process for the preparation of cyclic depsipeptides
granted -
US 11739123
Process for the preparation of cyclic depsipeptides
granted -
US 11339150
Benzimidazole compounds as HDAC6 inhibitors
granted -
US 11203602
Thioester prodrugs of macrocycles as inhibitors of histone deacetylases
granted -
US 11053284
Process for the preparation of cyclic depsipeptides
granted -
US 10689419
Process for the preparation of cyclic depsipeptides
granted -
US 10100089
Process for the preparation of cyclic depsipeptides
granted
Frequently asked questions
How many patents does OnKure Therapeutics have?
7 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do OnKure Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.